Form 4: Myomo CMO Harry Kovelman Sells 32,000 Shares

Chief Medical Officer Harry Kovelman reduced his stake in Myomo, Inc. through open market sales totaling 32,000 shares over two days.

Summary

• Harry Kovelman, the Chief Medical Officer of Myomo, Inc., sold a total of 32,000 shares of common stock.
• The transactions took place on May 27 and May 28, 2026.
• On May 27, 20,464 shares were sold at a weighted average price of $1.002.
• On May 28, 11,536 shares were sold at a weighted average price of $1.0172.
• Following these sales, Kovelman continues to hold 108,618 shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative; while the sale is relatively small, any divestment by a Chief Medical Officer at low price levels can dampen investor sentiment.

Positives

• The reporting person maintains a significant remaining ownership of 108,618 shares, indicating continued skin in the game.
• The sales were conducted transparently in the open market with price ranges disclosed.

Negatives

• A key executive (Chief Medical Officer) is liquidating a portion of his equity holdings.
• The sales occurred at a relatively low price point, near the $1.00 threshold.

Risks

• Insider selling can be interpreted by the market as a lack of confidence in the company's near-term valuation or upcoming clinical/regulatory milestones.
• Potential downward pressure on the stock price if the market perceives this as the start of a broader divestment trend by management.

Future Outlook

No specific forward-looking guidance or strategic updates were provided in this transaction-focused filing.

Industry Context

StockSavvy.ai notes that in the medical technology sector, insider sales by clinical leadership are often scrutinized more heavily than those by financial officers, as they may be perceived to relate to the executive's view on product efficacy or regulatory timelines.

Comparison to Industry Standards

• The sale represents a moderate reduction in the executive's total position, which is common for personal liquidity in micro-cap companies.
• The transaction volume is small relative to the average daily trading volume of typical NASDAQ-listed medical device firms.

Related Party Transactions

• The reporting person, Harry Kovelman, is the Chief Medical Officer of the issuer.

Stakeholder Impact

• Shareholders may experience minor negative sentiment due to insider selling activity.

Next Steps

• Monitor for additional Form 4 filings from other Myomo executives to determine if this is an isolated sale.
• Watch for upcoming clinical or regulatory announcements that may explain the timing of this transaction.

Key Dates

Recommendation

The insider sale is not large enough to warrant a sell rating, especially given the CMO's substantial remaining stake. However, it suggests a lack of immediate bullishness, making a hold recommendation appropriate until further fundamental catalysts emerge.

Keywords

Myomo, MYO, Insider Selling, Harry Kovelman, Chief Medical Officer, SEC Form 4, Medical Devices, Common Stock